Key result
Treatment with interleukin-3 and chemotherapy in a patient with breast cancer was associated with the development of acute cerebellar and superior mesenteric artery thrombosis.
Case Report (n=1)
Interleukin-3 may be associated with an increased propensity for arterial thrombosis when used to ameliorate neutropenia in patients receiving chemotherapy.
May warrant thrombosis vigilance with IL-3 in chemotherapy; hypothesis-generating and should not change practice.
BACKGROUND: Interleukin-3 (IL-3) is an experimental agent used to ameliorate neutropenia in patients receiving chemotherapy. Arterial thrombotic episodes after use of IL-3 have not been reported previously. METHODS: The case of a patient with Stage III adenocarcinoma of the breast who developed hypotension and acute cerebellar artery and superior mesenteric artery thrombosis after receiving chemotherapy and treatment with IL-3 is reported. RESULTS: To the authors' knowledge, this is the first patient with arterial thrombosis reported after treatment with IL-3. CONCLUSIONS: Interleukin-3 may be associated with increased propensity for thrombosis.
No takes yet. Share an insight, caveat, or question.
Theodossiou et al. (1994) conducted a case report in Stage III adenocarcinoma of the breast (n=1). Interleukin-3 (IL-3) and chemotherapy was evaluated on Acute cerebellar artery and superior mesenteric artery thrombosis. Treatment with interleukin-3 and chemotherapy in a patient with breast cancer was associated with the development of acute cerebellar and superior mesenteric artery thrombosis.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: